|
|
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on whether a supercomputer such as Watson will be able to use complex algorithms to improve cancer care.
Podcast: Play in new window | Download (Duration: 1:24 — 15.9MB) | Embed
There are many overwhelming aspects to a new diagnosis of cancer, and one of the key ones is the range of health care professionals involved in cancer care. On the plus side, it’s helpful that cancer now typically involves a team of people with complementary roles and skills, but it can be hard to keep track of who does what. Here’s a link to a post I did for LUNGevity at their request, describing the roles of the most common players on the team of professionals working with a patient being diagnosed with lung cancer.
The cast of characters is pretty similar for other cancer types as well, except that someone like a gastroenterologist replaces the role of the pulmonologist for someone with a suspected colon cancer, a urologist (a surgical specialist in the genitourinary system) replaces the thoracic surgeon for someone with a suspected bladder cancer, etc. But the general rule always applies that especially for a role like a surgeon or radiation oncologist, where technique is a critical element, outcomes tend to be best for those who are more specialized and experienced.
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on more widespread availability of new mutation tests.
Podcast: Play in new window | Download (Duration: 1:49 — 21.0MB) | Embed
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, on what he sees as the most significant changes in cancer care in the last decade or two.
Podcast: Play in new window | Download (Duration: 1:06 — 12.8MB) | Embed
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses leading challenges he sees for effective delivery of the best cancer care over the next decade.
Podcast: Play in new window | Download (Duration: 1:59 — 22.9MB) | Embed
Dr. Larry Einhorn, Indiana University, expresses his concerns about the cost of developing cancer drugs and the challenge of paying for extremely expensive cancer treatments that are given in anticipation of modest clinical benefits.
Podcast: Play in new window | Download (Duration: 2:29 — 28.6MB) | Embed
Dr. Larry Einhorn, Indiana University, explains why some cancers such as testicular cancer can have such a high cure rate while most others are far more challenging to cure with our current systemic therapies, offering an optimistic view of the future.
Podcast: Play in new window | Download (Duration: 2:31 — 29.0MB) | Embed
Our webinar with Dr. Suresh Ramalingam, Director of Hematology & Oncology at Emory and Chair of the ECOG Lung Cancer Committee, closed with a question and answer session that covered some of the emerging challenges of doing trials in a new era of molecular oncology. The division of a big field like lung cancer into many subgroups, including some small ones like the 4% with an ALK rearrangement and perhaps even 1-3% populations with others on the horizon, has led to many of our greatest advances in the past 5-10 years. It has also, however, introduced new challenges, as we try to do studies of relatively rare patients who are geographically dispersed and often won’t have an available trial for them that is conveniently located nearby?
How will the field of oncology adapt? Dr. Ramalingam offers his insights in the following podcast, offered in audio form, along with the transcript for the program (because there really isn’t anything visual in this part, there’s no real video to see — it’s just converted into a video format as part of the subscription channel for those people who have an automated feed to all of our video podcasts).
Podcast: Play in new window | Download (Duration: 10:01 — 9.2MB) | Embed
The last portion of Dr. Suresh Ramalingam’s presentation covered several persistent myths around clinical research in cancer, countered with the real facts, and then included a highlighting of patient rights in clinical trials.
Here are the video and audio versions of this last portion of his presentation, along with the transcript and figures.
Podcast: Play in new window | Download (Duration: 13:03 — 49.3MB) | Embed
Ramalingam Clin Trials in Cancer Pt 3 Audio Podcast
Ramalingam Clin Trials in Cancer Pt 3 Transcript
Our friend Dr. Suresh Ramalingam from Winship Cancer Center, Emory University in Atlanta, GA continued his primer on clinical trials in cancer by discussing the components involved with developing a clinical trial. Here he covers how we develop everything from the basic premise of what the trial will test, how we develop the statistical tests, the documentation we develop, and the regulatory requirements leading to a clinical trial becoming available for patient enrollment at an institution.
Below you’ll find the video and audio versions of the podcast, along with the transcript and figures for the program.
Podcast: Play in new window | Download (Duration: 15:29 — 55.6MB) | Embed
Ramalingam Clin Trials Pt 2 Trial Development Audio Podcast
Ramalingam Clin Trials Pt 2 Trial Development Transcript
| Follow us on... |    |
||
Copyright ©2013 GRACE |
|||
